Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 4/20 | 0.35 |
| ▸ | CDK19 | Q9BWU1 | 4/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | CCNC | P24863 | 3/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18072235 | 0.85 | TSHR (0.47) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL23131110 | 0.85 | LMNA (0.47) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17760301 | 0.85 | LMNA (0.38) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL22770999 | 0.82 | LMNA (0.40) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL16614241 | 0.82 | LMNA (0.45) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL4141809 | 0.82 | LMNA (0.45) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL16001316 | 0.82 | TSHR (0.45) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL1911519 | 0.81 | LMNA (0.44) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL25374346 | 0.81 | LMNA (0.41) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL22174114 | 0.81 | LMNA (0.44) | LMNACHRM2ADRA2ACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225752-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | Idorsia Pharmaceuticals Ltd (CH) | 2023-08-16 | — | — | EP | claimed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| WO-2022073969-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-04-14 | — | — | WO | claimed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | claimed |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | claimed |
| EP-3661941-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-06-10 | — | — | EP | claimed |
| WO-2019025099-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | claimed |
| US-12312362-B2 | Spiro derivatives of Alpha-D-galactopyranosides | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-27 | — | — | US | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| EP-4271673-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | Tyra Biosciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230295182-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-21 | — | — | US | disclosed |
| EP-4225752-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | Idorsia Pharmaceuticals Ltd (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-3207030-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017021805-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2016060941-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-04-21 | — | — | WO | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | LMNA 2311/4885CHRM2 3154/4885ADRA2A 2850/4885 |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, AMPD2 | LMNA 3726/4885CHRM2 2214/4885ADRA2A 332/4885 |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | LMNA 1232/4885CHRM2 4679/4885ADRA2A 3941/4885 |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, AMPD2 | LMNA 3726/4885CHRM2 2214/4885ADRA2A 332/4885 |
| US-12312362-B2 | Spiro derivatives of Alpha-D-galactopyranosides | LGALS1, LGALS3, LGALS2 | LMNA 924/4885CHRM2 1679/4885ADRA2A 211/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | LMNA 2441/4885CHRM2 444/4885ADRA2A 895/4885 |
| US-20230295182-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | LGALS1, LGALS3, LGALS2 | LMNA 924/4885CHRM2 1679/4885ADRA2A 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.